ACTG A5095 -PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV

ACTG A5095 - HIV 初始治疗的蛋白酶抑制剂保留方案

• 批准号: 7719426
• 负责人: THOMAS A CAMPBELL
• 金额: $ 0.07万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719426
• 关键词: Anti-HIV Agents; Blood; Computer Retrieval of Information on Scientific Projects Database; Daily; Drug Combinations; Funding; Grant; HIV; Institution; Learning; Pharmaceutical Preparations; Placebos; Protease Inhibitor; Purpose; Randomized; Research; Research Personnel; Resources; Source; Tablets; Treatment Protocols; United States National Institutes of Health; Viral Load result; capsule

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to learn how well each combination of drugs lowers the amount of HIV in the blood and keeps it low and how well the drug combinations are tolerated and if they are safe. Subjects must be never have taken anti-HIV drugs, and have a viral load greater than 400 copies. Subjects will be randomized by chance to one of the following treatment groups: Group A: ABC+3TC+ZDV combination tablet 3TC+ZDV placebo tablet (no active drug) EFV capsules once daily; Group B: ABC+3TC+ZDV combination tablet 3TC+ZDV placebo tablet EFV placebo capsules; Group C: ABC+3TC+ZDV placebo 3TC+ZDV combination tablet EFV capsules. This study lasts about 3.5 years.

这个子项目是众多研究子项目之一